Alzamend Neuro (NASDAQ:ALZN) Price Target Lowered to $35.00 at Ascendiant Capital Markets

Posted by ABMN Staff on Nov 13th, 2024

Alzamend Neuro (NASDAQ:ALZN – Get Free Report) had its price target dropped by equities researchers at Ascendiant Capital Markets from $50.00 to $35.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Alzamend Neuro Stock Up 2.0 %

NASDAQ ALZN opened at $1.53 on Monday. The company has a 50-day moving average price of $1.73 and a 200-day moving average price of $3.51. Alzamend Neuro has a 52 week low of $1.40 and a 52 week high of $19.20.

Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last announced its earnings results on Wednesday, September 11th. The company reported ($1.25) EPS for the quarter, beating analysts’ consensus estimates of ($2.38) by $1.13. On average, equities analysts predict that Alzamend Neuro will post -14.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alzamend Neuro stock. Virtu Financial LLC bought a new position in Alzamend Neuro, Inc. (NASDAQ:ALZN – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned 0.38% of Alzamend Neuro as of its most recent filing with the SEC. 49.61% of the stock is currently owned by hedge funds and other institutional investors.

Alzamend Neuro Company Profile

(Get Free Report)

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.